Neoadjuvant Cisplatinum Based Combination Chemotherapy in Patients with Invasive Bladder Cancer: A Combined Analysis of Two Nordic Studies

European Urology

Volumn 45, Issue 3, 2004, Pages 297-303

  Sherif, Amir ^a   Holmberg, Lars ^a   Rintala, Erkki ^b   Mestad, Oddvar ^c   Nilsson, Jonas ^a   Nilsson, Sten ^d   Malmström, Per Uno ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bladder cancer; Cystectomy; Neoadjuvant chemotherapy

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE;

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DRUG EFFICACY; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME;

EID: 1242292959     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.09.019     Document Type: Article

References (19)

1. Ghoneim M.A., El-Mekresh M.M., Mokhtar A.A., Gomha M.A., El-Baz M.A., El-Attar I.A. A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int. 85(7):2000;811-816.
2. Bassi P., Ferrante G.D., Piazza N., Spinadin R., Carando R., Pappagallo G.et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J. Urol. 161(5):1999;1494-1497.
3. Stein J.P., Lieskovsky G., Cote R., Groshen S., Feng A.C., Boyd S.et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3):2001;666-675.
4. Sternberg C.N., Calabro F. Neo-adjuvant chemotherapy in invasive bladder cancer. World J. Urol. 19(2):2001;94-98.
5. Anderström C., Johansson S., Nilsson S., Unsgaard B., Wahlqvist L. A prospective randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma. Eur. Urol. 9(3):1983;142-147.
6. Smith J.A. Jr., Batata M., Grabstald H., Sogani P.C., Herr H., Whitmore W.F. Jr. Preoperative irradiation and cystectomy for bladder cancer. Cancer. 49(5):1982;869-873.
7. Soloway M.S., Ikard M., Ford K. Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. Cancer. 47(3):1981;476-480.
8. Fagg S.L., Dawson-Edwards P., Hughes M.A., Latief T., Rolfe E.B., Fielding J.W. Cis diamminedichloroplatinum (DPP) as initial treatment of invasive bladder cancer. Br. J. Urol. 56:1984;296-300.
9. Raghavan D., Pearson B., Coorey G., Woods W., Arnold D., Smith J.et al. Intravenous cis-platinum for invasive clinically non-metastatic bladder cancer: safety and feasibility of a new approach. Med. J. Aust. 140(5):1984;276-278.
10. Abol-Enein H., El-Mekresh M., El-Baz M., Ghoneim M.A. Neoadjuvant chemotherapy in treatment of invasive transitional bladder cancer. A controlled prospective randomized study. Br. J. Urol. 80(Suppl. 2):1997;49.
11. International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group and Club Urologico Espanol de Tratamiento Oncologico (CUETO) group. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999;354(9178):533-40.
12. Sengeløv L., von der Maase H., Lundbeck F., Barlebo H., Colstrup H., Engelholm S.A.et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle- invasive bladder tumours. Acta Oncol. 41(5):2002;447-456.
13. Martinez-Pineiro J.A., González M., Arocena F., Flores N., Roncero C.R., Portillo J.A.et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomised phase III study. J. Urol. 153:1995;964-973.
14. Malmström P.U., Rintala E., Wahlqvist R., Hellström P., Hellsten S., Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J. Urol. 155:1996;1903-1906.
15. Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L.et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9):2003;859-866.
16. Sherif A., Rintala E., Mestad O., Nilsson J., Holmberg L., Nilsson S.et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer. Nordic cystectomy trial 2. Scand. J. Urol. Nephrol. 6:2002;419-425.
17. Hall R.R. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Prog. Proc. Am. Soc. Clin. Oncol. 21:2002;178a.
18. Advanced Bladder Cancer Meta-Analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta- analysis. Lancet 2003;361(9373):1927-3.
19. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351(9114):1451- 67.